Table 6.
MIF inhibitors in ongoing human clinical trials.
| Name | Highest clinic trial | Conditions | NCT Number | Study Start |
|---|---|---|---|---|
| Ibudilast (KC-404; AV-411; MN-166) |
Phase 2b/3 Recruiting |
ALS | NCT04057898 | 2020 |
| Phase 2 Recruiting |
Alcohol Use Disorder (AUD) |
NCT05414240 NCT03594435 |
2023 2018 |
|
| Phase 2 Recruiting |
Methamphetamine Addiction | NCT03341078 | 2019 | |
| Phase 1/2 Recruiting |
Newly Diagnosed and Recurrent Glioblastoma | NCT03782415 | 2018 | |
| Iguratimod (T-614) |
Phase 4 Recruiting |
Primary Sjögren's Syndrome | NCT04981145 | 2022 |
| Phase 4 Recruiting |
Rheumatoid Arthritis |
NCT05626348 NCT04927000 NCT04928066 |
2021 2021 2020 |
|
| Phase 2/3 Not yet recruiting |
Hand Osteoarthritis | NCT05216757 | 2022 | |
| Phase 2 Not yet recruiting Recruiting |
Steroid-resistant/Relapse Immune Thrombocytopenia |
NCT05302024 NCT05281068 |
2022 2021 |
|
| Not Applicable Not yet recruiting |
Diffuse cutaneous systemic sclerosis | NCT04515706 | 2021 |